• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Carasent

23.70 SEK

+2.60 %

1,642 following

CARA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.60 %
+0.21 %
+4.41 %
-13.66 %
-12.71 %
-15.21 %
+51.92 %
-23.32 %
+7.16 %

Carasent is an IT company. The company delivers products and services within communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security and backup solutions. Customers are mainly found within health and care, finance and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

Read more
Market cap
1.67B SEK
Turnover
1.83M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
Carnegielta commissioned research pre-Q4 Inderes Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -... Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie...
1/29/2025, 6:41 AM
by timontti
6
redeye.se Carasent (Q3 Review): In good shape for exciting 2026 Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives tha Carasent’s profitability...
10/16/2025, 3:46 PM
by Diviner
2
I have thousands of euros worth of Carasent ASA. It is no longer traded, so I am stuck with the shares. I thought there would have been an automatic exchange to Carasent AB… Is anyone else in the same situation? What should I do? How can I prevent this in the future?
6/23/2025, 7:38 AM
by Loue
1
redeye.se Carasent: Back in Shape in 2024 – More to Come Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised New Base Case SEK28 (NOK26...
2/17/2025, 6:47 AM
by timontti
1
Redeye expectations for the Q1 report on Feb 13th
2/6/2025, 3:08 PM
by timontti
1
Inderes First day of trading in Carasent AB (publ) on Nasdaq Stockholm - Inderes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND...
12/9/2024, 9:27 AM
by timontti
1
Which intermediary? Contact them, and the matter should be resolved.
6/23/2025, 1:51 PM
by Turskanpyytäjä
0
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.7.
2026

Interim report Q2'26

15.10.
2026

Interim report Q3'26

4.2.
2027

Annual report '26

Press release24.06.2026 klo 07.48

DNB Carnegie Access: Carasent: Infosolutions adds another layer to the story – Q2 preview

Carasent
Carasent, Audiocast, Q2'26
Webcast10.07.2026 klo 09.00

Carasent, Audiocast, Q2'26

Carasent
Regulatory press release09.06.2026 klo 15.58

Carasent completes the acquisition of Infosolutions

Carasent

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release29.05.2026 klo 08.00

Change in the number of shares and votes in Carasent AB (publ)

Carasent
Press release27.04.2026 klo 19.23

Redeye: Carasent: Broadening with lab solution in Sweden

Carasent
Press release27.04.2026 klo 11.17

DNB Carnegie Access: Carasent: Announces acquisition of Infosolutions

Carasent
Regulatory press release27.04.2026 klo 09.00

Carasent acquires Infosolutions and strengthens its position in Swedish private healthcare

Carasent
Regulatory press release20.04.2026 klo 12.08

Annual General Meeting in Carasent AB (publ)

Carasent
Press release15.04.2026 klo 12.09

Redeye: Carasent (Q1 review): Medsum momentum and German milestone

Carasent
Press release15.04.2026 klo 07.51

DNB Carnegie Access: Carasent: Focus on recurring revenue – Q1 review

Carasent
Press release14.04.2026 klo 14.26

Redeye: Carasent (Q1 initial take): Strong ARR, but profitability below expectations on higher costs and softer consulting

Carasent
Press release14.04.2026 klo 09.46

DNB Carnegie Access: Carasent: Miss on headline but recurring revenue strong – Q1 initial

Carasent
Carasent, Audiocast, Q1'26
Webcast14.04.2026 klo 09.00

Carasent, Audiocast, Q1'26

Carasent
Regulatory press release14.04.2026 klo 08.00

Carasent AB (publ) – interim report Q1 2026

Carasent
Regulatory press release08.04.2026 klo 10.15

Carasent AB (publ) – Invitation to presentation of Q1 2026 results

Carasent
Press release31.03.2026 klo 20.27

DNB Carnegie Access: Carasent: Ticks a lot of boxes in an uncertain environment – Q1 preview

Carasent
Regulatory press release19.03.2026 klo 19.00

Notice of Annual General Meeting in Carasent AB (publ)

Carasent
Regulatory press release19.03.2026 klo 09.00

Carasent publishes Annual Report for 2025

Carasent
Press release16.02.2026 klo 11.43

Redeye: Carasent (Q4 review): New products and sales initiatives to drive growth in 2026

Carasent
Press release12.02.2026 klo 22.11

DNB Carnegie Access: Carasent: Little to complain about in Q4

Carasent